var data={"title":"Abatacept: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Abatacept: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/200281?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=abatacept-patient-drug-information\" class=\"drug drug_patient\">see &quot;Abatacept: Patient drug information&quot;</a> and <a href=\"topic.htm?path=abatacept-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Abatacept: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452297\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Orencia;</li>\n      <li>Orencia ClickJect</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5663024\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Orencia</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452301\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antirheumatic, Disease Modifying;</li>\n      <li>\n        Selective T-Cell Costimulation Blocker</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452743\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriatic arthritis (PsA):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Dosing is according to body weight. Following the initial IV infusion (using the weight-based dosing), repeat IV infusion (using the same weight-based dosing) at 2 weeks and 4 weeks after the initial infusion, and every 4 weeks thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;60 kg: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">60 to 100 kg: 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;100 kg: 1,000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: 125 mg once weekly. <b>Note:</b> Administer without an IV loading dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>If transitioning from IV therapy to SubQ therapy,</i> administer the first SubQ dose instead of the next scheduled IV dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis (RA):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Dosing is according to body weight. Following the initial IV infusion (using the weight-based dosing), repeat IV infusion (using the same weight-based dosing) at 2 weeks and 4 weeks after the initial infusion, and every 4 weeks thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;60 kg: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">60 to 100 kg: 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;100 kg: 1,000 mg</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">SubQ: 125 mg once weekly. <b>Note:</b> SubQ dosing may be initiated with or without an IV loading dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>If initiating with an IV loading dose,</i> administer the initial IV infusion (using the weight-based dosing), then administer 125 mg subcutaneously within 24 hours of the infusion, followed by 125 mg subcutaneously once weekly thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>If transitioning from IV therapy to SubQ therapy,</i> administer the first SubQ dose instead of the next scheduled IV dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027843\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=abatacept-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Abatacept: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Juvenile idiopathic arthritis (JIA):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: <b>Note:</b> Dosage is according to body weight. Repeat dose at 2 weeks and 4 weeks after initial dose and every 4 weeks thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;6 years and &lt;75 kg: 10 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;6 years and &ge;75 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">75 to 100 kg: 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;100 kg: 1,000 mg (maximum dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Children &ge;2 years, and Adolescents: <b>Note:</b> Administer without an IV loading dose and use weight-based dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">10 to &lt;25 kg: 50 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;25 to &lt;50 kg: 87.5 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;50 kg: 125 mg once weekly</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452744\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Due to potential for higher rates of infections and malignancies, use caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15670390\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15670391\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452745\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\"> Discontinue in patients who develop a serious infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452751\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Orencia ClickJect: 125 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Orencia: 50 mg/0.4 mL (0.4 mL); 87.5 mg/0.7 mL (0.7 mL); 125 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Orencia: 250 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452299\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452746\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over 30 minutes. Administer through a 0.2 to 1.2 micron low protein-binding filter</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Allow prefilled syringe and autoinjector to warm to room temperature (for 30 to 60 minutes and 30 minutes, respectively) prior to administration. Inject into the front of the thigh (preferred), abdomen (except for 2-inch area around the navel), or the outer area of the upper arms (if administered by a caregiver). Rotate injection sites (&ge;1 inch apart); do not administer into tender, bruised, red, or hard skin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452304\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Juvenile idiopathic arthritis:</b> Treatment of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA); may be used as monotherapy or in combination with methotrexate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriatic arthritis:</b> Treatment of active psoriatic arthritis (PsA) in adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b> Treatment of moderately to severely active adult rheumatoid arthritis (RA); may be used as monotherapy or in combination with other DMARDs</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Abatacept should <b>not</b> be used in combination with anakinra or TNF-blocking agents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25808630\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Uveitis (children/adolescents)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5663023\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Orencia may be confused with Oracea</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452314\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined; COPD patients experienced a higher frequency of COPD-related adverse reactions (COPD exacerbation, cough, dyspnea, pneumonia, rhonchi)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (&le;18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (2% to 41%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (adults 54%; children 36%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (12%), upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (6%), abdominal pain, diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Immunogenicity (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes simplex infection, influenza</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (3% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (7%), limb pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (8%), bronchitis, pneumonia, rhinitis, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion-related reaction (&le;9%), fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute lymphocytic leukemia, anaphylactoid reaction, anaphylaxis, cellulitis, diverticulitis, dyspnea, exacerbation of arthritis, exacerbation of chronic obstructive pulmonary disease, flushing, hypersensitivity reaction, hypotension, joint wear, malignant lymphoma, malignant melanoma, malignant neoplasm of bile duct, malignant neoplasm of bladder, malignant neoplasm of breast, malignant neoplasm of cervix, malignant neoplasm of kidney, malignant neoplasm of lung, malignant neoplasm of prostate, malignant neoplasm of skin, malignant neoplasm of thyroid, malignant neoplasm of uterus, myelodysplastic syndrome, ovarian cyst, pruritus, pyelonephritis, rhonchi, urticaria, varicella, vasculitis (including cutaneous vasculitis and leukocytoclastic vasculitis), wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452310\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed within the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to abatacept or any component of the formulation; patients with, or at risk of sepsis syndrome (eg, immunocompromised, HIV positive)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452311\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Rare cases of hypersensitivity, anaphylaxis, or anaphylactoid reactions have been reported with intravenous administration; may occur with first infusion. Some reactions (hypotension, urticaria, dyspnea) occurred within 24 hours of infusion. Discontinue treatment if anaphylaxis or other serious allergic reaction occurs; medication for the treatment of hypersensitivity reactions should be available for immediate use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Serious and potentially fatal infections (including tuberculosis and sepsis) have been reported, particularly in patients receiving concomitant immunosuppressive therapy. RA patients receiving a concomitant TNF antagonist experienced an even higher rate of serious infection; monitor for signs and symptoms of infection when transitioning from TNF-blocking agents to abatacept. Caution should be exercised when considering the use in any patient with a history of new/recurrent infections, with conditions that predispose them to infections, or with chronic, latent, or localized infections. Patients who develop a new infection while undergoing treatment should be monitored closely. If a patient develops a serious infection, therapy should be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Use may affect defenses against malignancies (via T cell inhibition); impact on the development and course of malignancies is not fully defined. As compared to the general population, an increased risk of lymphoma and lung cancer has been noted in clinical trials; however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; COPD: Use caution with chronic obstructive pulmonary disease (COPD), higher incidences of adverse effects (COPD exacerbation, cough, rhonchi, dyspnea) have been observed; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution, higher incidences of infection and malignancy were observed in the elderly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis-positive patients: Safety has not been established in tuberculosis-positive patients; screen patients for latent tuberculosis infection prior to initiating therapy. Treat patients testing positive according to standard therapy prior to initiating abatacept.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Maltose: Powder for injection may contain maltose, which may result in falsely-elevated serum glucose readings on the day of infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis screening: Patients should be screened for viral hepatitis prior to use; antirheumatic therapy may cause reactivation of hepatitis B.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently or within 3 months of discontinuation of therapy; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298627\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452322\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8526&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anakinra: May enhance the adverse/toxic effect of Abatacept.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-TNF Agents: May enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Abatacept may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RiTUXimab: May enhance the adverse/toxic effect of Abatacept.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May enhance the adverse/toxic effect of Abatacept.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Abatacept may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452306\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Information related to the use of abatacept in pregnancy is limited (Kumar 2015). Until additional data are available, it is recommended to discontinue use and switch to a safer medication prior to conception unless no other pregnancy compatible medication is able to control maternal disease (G&ouml;testam Skorpen 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A pregnancy registry has been established to monitor outcomes of women exposed to abatacept during pregnancy (1-877-311-8972).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452309\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if abatacept is present in human milk. Until information is available, it is recommended to avoid breast-feeding during therapy unless no other compatible medication is able to control maternal disease. Breast-feeding should not be discouraged if no other agent is available (G&ouml;testam Skorpen 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452749\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs and symptoms of infection, signs and symptoms of hypersensitivity reaction; hepatitis and TB screening prior to therapy initiation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452741\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selective costimulation modulator; inhibits T-cell (T-lymphocyte) activation by binding to CD80 and CD86 on antigen presenting cells (APC), thus blocking the required CD28 interaction between APCs and T cells. Activated T lymphocytes are found in the synovium of rheumatoid arthritis patients. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2452329\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: 0.07 L/kg (range: 0.02 to 0.13 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: 78.6% (relative to IV administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: RA: 13.1 days (range: 8 to 25 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance: 0.22 to 0.23 mL/hour/kg; Children 6 to 17 years: JIA: 0.4 mL/hour/kg (increases with baseline body weight)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4370388\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Orencia Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $1,255.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Orencia ClickJect Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/mL (1 mL): $1,239.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Orencia Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/0.4 mL (0.4 mL): $1,239.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">87.5 mg/0.7 mL (0.7 mL): $1,239.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/mL (1 mL): $1,239.31</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539967\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Orencia (AE, AR, AT, AU, BB, BE, BR, CH, CL, CO, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HK, HN, HR, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, NL, NO, NZ, PE, PL, PT, RO, SA, SE, SG, SI, SK, TH, TR, TW);</li>\n      <li>Orencia SC (JP);</li>\n      <li>Orencia Subq PFS (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Doan T and Massarotti E, &ldquo;Rheumatoid Arthritis: An Overview of New and Emerging Therapies,&rdquo; <i>J Clin Pharmacol</i>, 2005, 45(7):751-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abatacept-drug-information/abstract-text/15951465/pubmed\" target=\"_blank\" id=\"15951465\">15951465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furst DE, Breedveld FC, Kalden JR, et al, &ldquo;Updated Consensus Statement on Biological Agents for the Treatment of Rheumatic Diseases, 2007,&rdquo; <i>Ann Rheum Dis</i>, 2007, 66(Suppl 3):2-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abatacept-drug-information/abstract-text/17934088/pubmed\" target=\"_blank\" id=\"17934088\">17934088</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Genovese MC, Becker JC, Schiff M, et al, &ldquo;Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor Alpha Inhibition,&rdquo; <i>N Engl J Med</i>, 2005, 353(11):1114-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abatacept-drug-information/abstract-text/16162882/pubmed\" target=\"_blank\" id=\"16162882\">16162882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    G&ouml;testam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. <i>Ann Rheum Dis</i>. 2016;75(5):795-810. doi: 10.1136/annrheumdis-2015-208840.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abatacept-drug-information/abstract-text/26888948/pubmed\" target=\"_blank\" id=\"26888948\">26888948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kremer JM, Dougados M, Emery P, et al, &ldquo;Treatment of Rheumatoid Arthritis With the Selective Costimulation Modulator Abatacept: Twelve-Month Results of a Phase IIb, Double-Blind, Randomized, Placebo-Controlled Trial,&rdquo; <i>Arthritis Rheum</i>, 2005, 52(8):2263-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abatacept-drug-information/abstract-text/16052582/pubmed\" target=\"_blank\" id=\"16052582\">16052582</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kremer JM, Genant HK, Moreland LW, et al, &ldquo;Effects of Abatacept in Patients With Methotrexate-Resistant Active Rheumatoid Arthritis: A Randomized Trial,&rdquo; <i>Ann Intern Med</i>, 2006, 144(12):865-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abatacept-drug-information/abstract-text/16785475/pubmed\" target=\"_blank\" id=\"16785475\">16785475</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kremer JM, Westhovens R, Leon M, et al, &ldquo;Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation With Fusion Protein CTLA4Ig,&rdquo; <i>N Engl J Med</i>, 2003, 349(20):1907-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abatacept-drug-information/abstract-text/14614165/pubmed\" target=\"_blank\" id=\"14614165\">14614165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar M, Ray L, Vemuri S, Simon TA. Pregnancy outcomes following exposure to abatacept during pregnancy. <i>Semin Arthritis Rheum</i>. 2015;45(3):351-356. doi: 10.1016/j.semarthrit.2015.06.016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abatacept-drug-information/abstract-text/26210783/pubmed\" target=\"_blank\" id=\"26210783\">26210783</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orencia (abatacept) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(5):625-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abatacept-drug-information/abstract-text/22473917/pubmed\" target=\"_blank\" id=\"22473917\">22473917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tay L, Leon F, Vratsanos G, et al, &ldquo;Vaccination Response to Tetanus Toxoid and 23-Valent Pneumococcal Vaccines Following Administration of a Single Dose of Abatacept: A Randomized, Open-Label, Parallel Group Study in Healthy Subjects,&rdquo; <i>Arthritis Res Ther</i>, 2007, 9(2): R38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abatacept-drug-information/abstract-text/17425783/pubmed\" target=\"_blank\" id=\"17425783\">17425783</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinblatt M, Combe B, Covucci A, et al, &ldquo;Safety of the Selective Costimulation Modulator Abatacept in Rheumatoid Arthritis Patients Receiving Background Biologic and Nonbiologic Disease-Modifying Antirheumatic Drugs: A One-Year Randomized, Placebo-Controlled Study,&rdquo; <i> Arthritis Rheum</i>, 2006, 54(9):2807-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abatacept-drug-information/abstract-text/16947384/pubmed\" target=\"_blank\" id=\"16947384\">16947384</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8526 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2452297\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5663024\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2452301\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2452743\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F6027843\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2452744\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15670390\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15670391\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F2452745\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2452751\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2452299\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2452746\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2452304\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25808630\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5663023\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2452314\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2452310\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2452311\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298627\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2452322\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2452306\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2452309\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2452749\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2452741\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2452329\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F4370388\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539967\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8526|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=abatacept-patient-drug-information\" class=\"drug drug_patient\">Abatacept: Patient drug information</a></li><li><a href=\"topic.htm?path=abatacept-pediatric-drug-information\" class=\"drug drug_pediatric\">Abatacept: Pediatric drug information</a></li></ul></div></div>","javascript":null}